P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
Marina Konopleva,
Courtney D. Dinardo,
Yan Sun,
Sanam Loghavi,
Paul Jung,
Jalaja Potluri,
Monique Dail,
Brenda Chyla,
Daniel A. Pollyea
Affiliations
Marina Konopleva
1 Montefiore Einstein Cancer Center, Department of Oncology, The Bronx, NY, United States
Courtney D. Dinardo
2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, United States
Yan Sun
3 AbbVie Inc., North Chicago, IL, United States
Sanam Loghavi
4 The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, TX, United States
Paul Jung
3 AbbVie Inc., North Chicago, IL, United States
Jalaja Potluri
3 AbbVie Inc., North Chicago, IL, United States
Monique Dail
5 Genentech Inc, South San Francisco, CA, United States
Brenda Chyla
3 AbbVie Inc., North Chicago, IL, United States
Daniel A. Pollyea
6 School of Medicine, University of Colorado, Hematology, Aurora, CO, United States
